Gervaz P, Scholl B, Padrun V, Gillet M
Department of Surgical Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Liver. 2000 Apr;20(2):108-13. doi: 10.1034/j.1600-0676.2000.020002108.x.
This study was undertaken in order to assess the efficacy of a potent angiogenesis inhibitor, TNP-470, on tumor growth in a syngeneic rodent model of liver metastases from colorectal cancer.
New blood vessel formation is a prerequisite for primary and metastatic tumor growth. TNP-470, a synthetic derivative of fumagillin when subcutaneously transplanted into nude mice, inhibits endothelial cell proliferation and migration, as well as the growth of various human cancers. However, the antitumor effect of this drug has not been studied in models reproducing a natural metastatic environment. Since the liver provides an extensive vascular bed for secondary tumor growth, an anti-angiogenic strategy may therefore be less efficient for treating hepatic metastases than primary tumors.
10(7) DHD K12 colon carcinoma cells were injected intrasplenically into syngeneic BD IX rats to produce diffuse liver metastases. TNP-470 (30 mg/kg/day) was administered on alternate days starting 4 days after tumor implantation. The animals were sacrificed after 4 weeks and their livers were processed for histologic examination. In both the treatment and control groups (n=7), tumor volume was determined using a computerized analytical system, and tumor microvessel density was measured by immunostaining with anti-von Willebrand Factor monoclonal antibody.
In vitro, TNP-470 demonstrated a direct toxicity towards the DHD K12 cell line with an IC50 of 0.1 microg/ml. Metastases were present in all animals from both groups. Liver weight (15.2 g vs 11.7 g, p=0.01), and tumor volume (1218 mm3 vs 406 mm3, p=0.03) were significantly reduced in the TNP-470 group compared to the control group. Tumor microvessel density was not statistically different between the two groups (67 vs 63 microvessels/x200 field, p=0.41).
TNP-470 inhibits the growth of liver metastases in a syngeneic rat model of colorectal cancer. The mechanism responsible for this effect remains unclear, but may involve a combination of anti-angiogenic and direct cytotoxic effects.
本研究旨在评估一种强效血管生成抑制剂TNP - 470对结直肠癌肝转移同基因啮齿动物模型中肿瘤生长的疗效。
新血管形成是原发性和转移性肿瘤生长的先决条件。TNP - 470是烟曲霉素的合成衍生物,皮下移植到裸鼠体内时,可抑制内皮细胞增殖和迁移以及各种人类癌症的生长。然而,该药物在重现自然转移环境的模型中的抗肿瘤作用尚未得到研究。由于肝脏为继发性肿瘤生长提供了广泛的血管床,因此抗血管生成策略治疗肝转移可能不如治疗原发性肿瘤有效。
将10(7)个DHD K12结肠癌细胞脾内注射到同基因BD IX大鼠体内以产生弥漫性肝转移。从肿瘤植入后4天开始,每隔一天给予TNP - 470(30毫克/千克/天)。4周后处死动物,取其肝脏进行组织学检查。在治疗组和对照组(每组n = 7)中,使用计算机分析系统测定肿瘤体积,并用抗血管性血友病因子单克隆抗体免疫染色测量肿瘤微血管密度。
在体外,TNP - 470对DHD K12细胞系表现出直接毒性,IC50为0.1微克/毫升。两组所有动物均出现转移。与对照组相比,TNP - 470组的肝脏重量(15.2克对11.7克,p = 0.01)和肿瘤体积(1218立方毫米对406立方毫米,p = 0.03)显著降低。两组之间的肿瘤微血管密度无统计学差异(67对63个微血管/200视野,p = 0.41)。
TNP - 470在结直肠癌同基因大鼠模型中抑制肝转移的生长。造成这种效应的机制尚不清楚,但可能涉及抗血管生成和直接细胞毒性作用的联合。